Neuropsychopharmacology focuses on how drugs influence brain function, behavior, and mental health. It integrates neuroscience, psychiatry, and pharmacology to study treatments for psychiatric and neurological disorders. This includes antidepressants, antipsychotics, anxiolytics, mood stabilizers, and drugs for neurodegenerative diseases. The field also examines the neurobiological basis of addiction, cognition, and emotional regulation. Research combines molecular studies, brain imaging, and behavioral science to understand drug mechanisms and optimize therapy. Advances in personalized psychiatry and neuropharmacogenetics are opening new possibilities for targeted mental health treatments.
sub tracks:
Related Conferences:
World Congress on Pharmacology & Toxicology (WCPT) | International Conference on Clinical Pharmacology & Therapeutics (ICCPT) | Global Summit on Drug Discovery and Development (GSDDD) | European Conference on Toxicology & Applied Pharmacology (ECTAP) | International Symposium on Experimental and Clinical Toxicology (ISECT)
Related Associations:
International Union of Basic and Clinical Pharmacology (IUPHAR) | British Pharmacological Society (BPS) | American Society for Pharmacology and Experimental Therapeutics (ASPET) | European Society of Toxicology (EUROTOX) | Society of Toxicology (SOT) | Asia Pacific Association of Pharmacologists (APAP) | Federation of Asian Pharmacological Societies (FAPS) | International Society for the Study of Xenobiotics (ISSX)
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
